Skip to content
ClinCalc Pro
Menu
Iron chelator (parenteral)

Desferrioxamine mesilate

Brand names: Desferal

Desferrioxamine mesilate (deferoxamine) is a parenteral iron-chelating agent used to treat acute iron poisoning and chronic iron overload, such as that resulting from repeated blood transfusions.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds free iron (and aluminium) to form a stable complex, ferrioxamine, which is water-soluble and excreted by the kidneys, removing excess metal from the body.

Prescribing in practice

  • It is the antidote of choice in serious acute iron poisoning, and rapid intravenous infusion can cause hypotension, so the rate must be controlled.
  • Long-term use is associated with ocular and auditory toxicity (including retinopathy and hearing loss), so baseline and periodic eye and ear assessments are advised.
  • Urine may turn a reddish (vin rosé) colour reflecting iron excretion, and dosing follows current prescribing references for the indication.

Monitoring

Monitor for infusion-related hypotension, conduct periodic ophthalmological and audiometric assessment with prolonged use, and watch for opportunistic infections.

Counselling the patient

  • Your urine may turn a reddish colour, which is expected and harmless and shows iron is being removed.
  • Regular eye and hearing checks may be needed with long-term treatment.
  • Report any change in vision or hearing to your clinician.

Evidence & guidelines

Desferrioxamine is the long-established iron chelator recommended for significant acute iron poisoning and transfusional iron overload in UK toxicology and haematology practice.

Reference: SmPC Desferal; UK Thalassaemia Society Standards 2016; Cappellini et al. Guidelines for the Management of Transfusion Dependent Thalassaemia 2014; TOXBASE Iron Overdose; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

Desferrioxamine mesilate is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.